Stockscreener 앱 받기
4.24
6.80%
0.27
시간 외 거래:
4.19
-0.05
-1.18%
전일 마감가:
$3.97
열려 있는:
$3.97
하루 거래량:
2.90M
Relative Volume:
2.64
시가총액:
$195.51M
수익:
$82.71M
순이익/손실:
$-102.24M
주가수익비율:
-1.1553
EPS:
-3.67
순현금흐름:
$-76.57M
1주 성능:
+1.19%
1개월 성능:
-60.59%
6개월 성능:
-66.61%
1년 성능:
-68.71%
1일 변동 폭
$3.605
$4.24
1주일 범위
$3.605
$4.25
52주 변동 폭
$3.42
$20.70
Urogen Pharma Ltd Stock (URGN) Company Profile
명칭
Urogen Pharma Ltd
전화
972 9 770 7601
주소
9 HA'TA'ASIYA ST, RA'ANANA
URGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
4.24 | 193.19M | 82.71M | -102.24M | -76.57M | -3.67 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-22 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-04-16 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-19 | 재개 | Ladenburg Thalmann | Buy |
| 2024-08-22 | 개시 | Guggenheim | Buy |
| 2023-02-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-04-27 | 개시 | Berenberg | Buy |
| 2020-04-16 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-13 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-09 | 개시 | National Securities | Neutral |
| 2019-05-30 | 개시 | JP Morgan | Neutral |
| 2019-05-29 | 개시 | Goldman | Neutral |
| 2019-01-29 | 개시 | H.C. Wainwright | Buy |
| 2018-11-08 | 재개 | Jefferies | Buy |
| 2018-04-04 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-01-02 | 개시 | Ladenburg Thalmann | Buy |
| 2017-11-15 | 재확인 | Oppenheimer | Outperform |
| 2017-11-15 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
모두보기
Urogen Pharma Ltd 주식(URGN)의 최신 뉴스
Class Action Lawsuit Filed: UroGen Pharma Ltd. (URGN)Join by July 28, 2025Contact Levi & Korsinsky - ACCESS Newswire
URGN CLASS ACTION NOTICE: UroGen Pharma Ltd. has been Sued - GlobeNewswire
Levi & Korsinsky Investigates UroGen Pharma Ltd. (URGN) Over Possible Securities Fraud - ACCESS Newswire
Pharma Co. Hid Cancer Study Method Problems, Investor Claims - Law360
URGN ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of UroGen Pharma Ltd. Investors - Business Wire
URGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
URGN Investor Notice: Robbins LLP Reminds Stockholders of the Class Action Lawsuit Against ... - Eagle-Tribune
URGN FRAUD ALERT: UroGen Pharma Ltd. Investors are Alerted to Contact BFA Law about the Pending Securities Fraud Class Action - Newsfile
URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
UroGen Pharma Ltd. (URGN) Faces Securities Class Action - GlobeNewswire
URGN BREAKING NEWS: UroGen Pharma Ltd. Stock Plummets 45% Triggering Shareholder Class Action – Contact BFA Law if You Lost Money (NASDAQ:URGN) - Business Wire
UroGen Investor Sues After Cancer Therapy Setback, 45% Selloff - Bloomberg Law News
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against UroGen Pharma Ltd. (URGN) - GlobeNewswire Inc.
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
URGN Investors Have the Opportunity to Lead the UroGen Pharma Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - PR Newswire
UroGen Pharma Ltd. (NASDAQ:URGN) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
URGN Stockholder Alert: Robbins LLP Informs Investors of the UroGen Pharma Ltd. Class Action Lawsuit - Morningstar
UroGen Pharma Ltd. Investors: Please contact the Portnoy - GlobeNewswire
URGN INVESTOR ALERT: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – Company AnnouncementFT.com - Financial Times
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen - Business Wire
Law Offices of Howard G. Smith Encourages UroGen Pharma Ltd. (URGN) Investors To Inquire About Securities Fraud Class Action - Business Wire
UroGen Pharma Ltd. (URGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Did You Suffer Losses in UroGen Pharma Ltd. (URGN)? Contact Levi & Korsinsky About Securities Fraud Claims - ACCESS Newswire
UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA's ODAC Vote Against UGN-102, Company Facing Investor ScrutinyHagens Berman - PR Newswire
Did UroGen Pharma Ltd. (URGN) Mislead Investors? Levi & Korsinsky Investigates - ACCESS Newswire
Oppenheimer maintains Outperform on UroGen Pharma stock By Investing.com - Investing.com India
Lost Money on UroGen Pharma Ltd. (URGN)? Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
UroGen Pharma to Present at TD Cowen: 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA - New Castle News
UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA’s - GlobeNewswire
UroGen Pharma Ltd. (NASDAQ:URGN) Stock Position Decreased by Millennium Management LLC - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against UroGen Pharma Ltd. (URGN) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd.URGN - PR Newswire
Janus Henderson Group PLC Acquires New Stake in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
Lazard Asset Management LLC Acquires New Holdings in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
Q2 EPS Estimates for UroGen Pharma Raised by HC Wainwright - Defense World
UroGen Pharma Stock Receives Downgrade As Analyst Cites FDA Panel Setback For Key Bladder Cancer Drug - Benzinga
Guggenheim Has Lowered Expectations for UroGen Pharma (NASDAQ:URGN) Stock Price - Defense World
The Goldman Sachs Group Cuts UroGen Pharma (NASDAQ:URGN) Price Target to $3.00 - Defense World
Ongoing Investigation: UroGen Pharma Ltd. (URGN) May Have Misled ShareholdersLevi & Korsinsky Investigates - ACCESS Newswire
Northern Trust Corp Purchases 23,345 Shares of UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
Kaplan Fox Reminds Investors of UroGen Pharma Ltd. (URGN) to an Investigation of Potential Securities Law Violations - FinancialContent
Guggenheim's Michael Schmidt Lowers Price Target for UroGen Pharma (URGN) | URGN Stock News - GuruFocus
Kaplan Fox is Investigating Potential Securities Law Violations against UroGen Pharma Ltd. (URGN) - FinancialContent
UroGen Pharma (URGN) Price Target Cut by Guggenheim | URGN Stock News - GuruFocus
URGN ACTIVE INVESTIGATION: Lost Money on UroGen Pharma Ltd.? Contact Levi & Korsinsky Now - ACCESS Newswire
UroGen crashes as FDA AdCom rebukes bladder cancer drug - MSN
UroGen Pharma Shares Fall After HC Wainwright Downgrade - marketscreener.com
Kaplan Fox Announces an Investigation Into UroGen Pharma Ltd. (URGN) for Potential Securities Law Violations - FinancialContent
UroGen Pharma (URGN) Target Price Slashed by Goldman Sachs | URGN Stock News - GuruFocus
Goldman Sachs cuts UroGen Pharma target to $3 from $16 - Investing.com Australia
UroGen tanks as FDA panel vote goes against UGN-102 - The Pharma Letter
Urogen Pharma Ltd (URGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
3.74%
자본화:
|
볼륨(24시간):